Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

60.0%

9 terminated/withdrawn out of 15 trials

Success Rate

35.7%

-50.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

120%

6 of 5 completed trials have results

Key Signals

1 recruiting6 with results5 withdrawn

Enrollment Performance

Analytics

Phase 1

13(86.7%)

Phase 2

2(13.3%)

15Total

Phase 1(13)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT04476901Phase 2Recruiting

Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy

Role: lead

NCT02677350Phase 1Withdrawn

AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PErifistula iNjEctions (GALENE)

Role: lead

NCT03406884Phase 1Completed

The CHILD Trial: Hypoplastic Left Heart Syndrome Study.

Role: lead

NCT04776239Phase 1Completed

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

Role: lead

NCT03059355Phase 1Terminated

Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.

Role: lead

NCT04490486Phase 1Withdrawn

Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19

Role: lead

NCT02886884Phase 1Completed

Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects

Role: lead

NCT02013700Phase 1Terminated

Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)

Role: lead

NCT02503280Phase 1Withdrawn

The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.

Role: lead

NCT03487731Phase 1Withdrawn

Allogeneic Human Mesenchymal Stem Cell Injection in PAtieNts With FaceTogenic Back Pain

Role: lead

NCT03058068Phase 1Withdrawn

Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis

Role: lead

NCT02013674Phase 2Completed

The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study)

Role: lead

NCT00587990Phase 1Terminated

Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)

Role: lead

NCT02675556Phase 1Terminated

Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression

Role: lead

NCT01392625Phase 1Completed

PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)

Role: lead

All 15 trials loaded